Christopher P. Austin, of Washington, D.C., is director of the National Institutes of Health (NIH) Genomics Center, Division of Intramural Research, where he also is an associate investigator of the Genome Technology Branch and serves as senior advisor to the director for translational research. He graduated from Princeton University in 1981 with a bachelor's degree in biology and in 1986 earned a medical degree at Harvard Medical School.
Steven D. Averbuch, of North Wales, Penn., is vice president in the Oncology Transition Strategy and Development and head of pharmacodiagnostics in Oncology Global Clinical Research for Bristol-Myers Squibb Company, based in Lawrenceville, N.J. He graduated from the University of Kansas in 1974 with a bachelor's degree in pharmacy and from the University of Illinois College of Medicine in 1979.
Anand C. Burman, of New Delhi, India, is Chairman of the Board of Dabur India Limited, in New Delhi, India. The firm has holdings in pharmaceuticals, Health Care Products and personal care and food products. He is also on the Board of Directors of Fresenius Kabi Oncology which is a leading company for cancer care and cancer research products. Burman graduated with a B.S. in Chemistry from the University of Wisconsin in Madison, and holds three degrees from the University of Kansas, including a 1977 master's degree in chemistry, and 1981 master's and doctoral degrees in pharmaceutical chemistry.
David Jenkins, of Flanders, N.J., is managing partner for FatBoy Capital, L.P., a venture capital partnership with approximately $30 million under management. The firm concentrates its investments primarily in three companies: Geodigm Inc., Inset Technologies, Inc., and Catheter Robotics, Inc. Jenkins graduated from the University of Kansas in 1979 with a bachelor's degree in business and earned his graduate degree from the University of Texas, Austin.
Michael D. Webb, of Sherborn, Mass., is executive chairman of Virtify, Inc., a provider of software solutions for regulatory compliance to life sciences companies. He is a founder and on the board of directors of Ascent Therapeutics and also serves on the boards of Estern Medical, Wolfe Laboratories and the Massachusetts Biotechnology Council. Webb graduated from the University of Kansas in 1980 with bachelor's degrees in biochemistry and economics, and in 1982 he earned a master's degree in international relations at Sussex University. In 1984, he graduated from Northwestern University with a master's degree in business administration.
Thomas Wiggans, of Atherton, Calif., is chief executive officer and chairman of the board of Peplin, Inc., a U.S. and Australian biotechnology company developing a product for skin cancers and other serious skin diseases. He is a member of the board of directors of Onyx Pharmaceuticals, and he is on the board of directors for two private companies, Victory Pharma and Corthera, Inc. He graduated from the University of Kansas in 1975 with a bachelor's degree in pharmacy, and received his master's in business administration from Southern Methodist University.
David Vranicar, of Olathe, Kansas is president of Heartland BioVentures and leads commercialization programs and investments for the Kansas Bioscience Authority. Mr. Vranicar led the development of the initial comprehensive financial plan for the University of Kansas Cancer Center and earlier worked at Marion Laboratories on numerous product licensing, joint marketing, and business development initiatives. Mr. Vranicar earned a bachelor’s degree from the University of Texas and a master’s degree in business from the University of Michigan.
©
The University of Kansas Medical Center